<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="373142">
  <stage>Registered</stage>
  <submitdate>15/06/2017</submitdate>
  <approvaldate>22/06/2017</approvaldate>
  <actrnumber>ACTRN12617000913370</actrnumber>
  <trial_identification>
    <studytitle>Bovine Lactoferrin for treatment of anaemia associated with advanced cancer</studytitle>
    <scientifictitle>Bovine Lactoferrin for the treatment of anaemia associated with cancer cachexia related to underlying stage IV non-small cell lung cancer'</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Anaemia</healthcondition>
    <healthcondition>Cancer Cachexia</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Anaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral administration of 250 mg, 500 mg of bovine lactoferrin once daily for 12 weeks

, one arm will receive 250 mg bovine Lactoferrin, one arm will receive 500 mg of bovine Lactoferrin and one arm will receive placebo. and the apparent healthy will receive 250 mg bovine Lactoferrin

All the group one tablet once daily

We will have one week trial for adherence to the drug by giving a period of one week placebo and those who are compliant with the placebo for one week by more than 85 % will be included in the study</interventions>
    <comparator>RCT, single blinded, two group of controls, apparent healthy, the other group patients with cacherxia related to underlying  stage IV non-small cell lung cancer

We have two controls, one will receive placebo and the apparent healthy will receive 250 mg of bovine lactoferrin
Cachexia control group will receive placebo  (microcellulose tablets).
Apparent healthy group will receive 250 mg bovine Lactoferrin</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>We will measure haemoglobin concentration by using blood samples on two occasions, 1st before starting the study as baseline and 2nd sample will be taken after 12 weeks (end of the study). </outcome>
      <timepoint>12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in serum level of iron</outcome>
      <timepoint>after 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in red blood cells (RBCs) count</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with cachexia related to underlying stage IV non-small cell lung cancer, 
Apparent healthy controls should not being diagnosed with any type of cancer or have been treated from cancer.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Metastasis in the brain or in bone, patients with severe illness, unstable angina, congestive heart failure, heart attack during the last month, cognitive impairment, unable to give a consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by the computer</concealment>
    <sequence>Computer sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>RCT</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>SPSS 23</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>False</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>18/06/2017</actualstartdate>
    <anticipatedenddate>29/12/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>130</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>22/03/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state>Cairo</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Deakin University</primarysponsorname>
    <primarysponsoraddress>School of Medicine, 75 Pigdons Road, Waurn Ponds VIC, 3220</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Deakin University</fundingname>
      <fundingaddress>75 Pigdons  Road, Waurn Ponds VIC 3220

Deakin University</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Our hypothesis is bovine lactoferrin may increase level of haemoglobin in patients with cachexia related to underlying stage IV non-small cell lung cancer. Our primary object is to compare the level of haemoglobin in comparison with the placebo, after adminstration of 250 my of bovine lactoferrin. The secondary object is the comparison with the placebo ,the effect of two different doses of bovine lactoferrin 250 mg versus 500 mg and will check the effect on increase in serum iron, red blood cell count and haemoglobin concentration. Also to compare the effect of 250 mg of bovine lactoferrin in cancer cachexia versus apparent healthy</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>National Cancer Institute, Cairo University, Egypt</ethicname>
      <ethicaddress />
      <ethicapprovaldate>17/01/2017</ethicapprovaldate>
      <hrec>201617001.2P</hrec>
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Jagat Kanwar</name>
      <address>75 Pigdons Road, Warun Ponds VIC 3220
Deakin University</address>
      <phone>+61352271148</phone>
      <fax />
      <email>jagat.kanwar@deakin.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ayman Aboda</name>
      <address>75 Pigdons Road, Warun Ponds, VIC 3220
Deakin University</address>
      <phone>+61404953667</phone>
      <fax>+61352271148</fax>
      <email>ayman.aboda@deakin.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ayman Aboda</name>
      <address>75 Pigdons Road, Warun Ponds, VIC 3220
Deakin University</address>
      <phone>+61404953667</phone>
      <fax />
      <email>ayman.aboda@deakin.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ayman Aboda</name>
      <address>75 Pigdons Road, Warun Ponds, VIC 3220</address>
      <phone>+61404953667</phone>
      <fax />
      <email>ayman.aboda@deakin.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>